MSCI-ESG rating upgraded to “AA”, reaching the global leading level
2022-07-08

MSCI-ESG rating upgraded to “AA”, reaching the global leading level

Won the “Best Pharmaceutical and Medical Company” award from Golden Hong Kong Listed Companies

Won the “Best Pharmaceutical and Medical Company” award from Golden Hong Kong Listed Companies

Won the “Excellent Pharmaceutical Industry Award” of “Top 100 Hong Kong Listed Companies”

Won the “Excellent Pharmaceutical Industry Award” of “Top 100 Hong Kong Listed Companies”

Shenzhen Kangzhe was awarded the “Shenzhen Top 500 Enterprises” and “Top 100 Corporate Taxpayers in Nanshan District”

Shenzhen Kangzhe was awarded the “Shenzhen Top 500 Enterprises” and “Top 100 Corporate Taxpayers in Nanshan District”

Tibet Kangzhe was awarded the “Excellent Development and Opening up Enterprise Award in Lhasa Economic and Technological Development Zone”

Tibet Kangzhe was awarded the “Excellent Development and Opening up Enterprise Award in Lhasa Economic and Technological Development Zone”

Included in “CNI Nanshan 50 Index” and “Hang Seng Large-Mid Cap (Investable) Index”

Included in “CNI Nanshan 50 Index” and “Hang Seng Large-Mid Cap (Investable) Index”

Obtained clinical trial notices of Cyclosporine Eye Drops 0.09% and Tildrakizumab Solution for Injection from China NMPA

Obtained clinical trial notices of Cyclosporine Eye Drops 0.09% and Tildrakizumab Solution for Injection from China NMPA

Invested in Gelesis, and acquired product rights of PLENITY, a weight management product, in Mainland China and/or other countries or regions

Invested in Gelesis, and acquired product rights of PLENITY, a weight management product, in Mainland China and/or other countries or regions

Acquired product rights of four innovative products including Desidustat Tablets, Methotrexate Injection(Pre-filled Syringe), BCG for Intravesical Instillation, and Methylthioninium Chloride Enteric-coated Sustained-release Tablets in Mainland China and/or other countries or regions

Acquired product rights of four innovative products including Desidustat Tablets, Methotrexate Injection(Pre-filled Syringe), BCG for Intravesical Instillation, and Methylthioninium Chloride Enteric-coated Sustained-release Tablets in Mainland China and/or other countries or regions

CMS Health, the cross-border e-commerce business entity for consumer healthcare products, was officially established

CMS Health, the cross-border e-commerce business entity for consumer healthcare products, was officially established